Abstract: A power storage device includes a power storage unit including one or a plurality of cells, a first controller for performing control relating to the power storage unit, a first power line for supplying a first power to be output from the power storage unit to a load, a second power line for supplying a second power smaller than the first power to a second controller included in an external device, and a communication line used by the first and second controllers to communicate with each other.

Abstract: A battery apparatus and an electric vehicle including the battery apparatus are provided. The battery apparatus including a first battery module and a second battery module that are connected in parallel and have different characteristics, wherein a first maximum output voltage of the first battery module is set to be larger than a second maximum output voltage of the second battery module, and a first use range of the first battery module is set to differ from a second use range of the second battery module.

Abstract: A power storage device includes a power storage unit including one or a plurality of cells, a first controller for performing control relating to the power storage unit, a first power line for supplying a first power to be output from the power storage unit to a load, a second power line for supplying a second power smaller than the first power to a second controller included in an external device, and a communication line used by the first and second controllers to communicate with each other.

Abstract: The present invention provides a highly safe pharmaceutical composition for preventing and/or treating bone disease, a pharmaceutical preparation comprising thereof, a health food comprising thereof, a functional food comprising thereof. Since the present invention comprises the arylheptanoid compound shown in the following formula (I) and the derivatives thereof, it enables to prevent and/or treat the bone disease. (In the formula (I), R1 and R5 are a functional group selected from the group consisting of a hydrogen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R2, R3, and R4 are a functional group selected from the group consisting of a hydrogen atom, an oxygen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R5 may be bound on meta-position against heptylene group of another aryl group to form a ring.

Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating periodontal disease comprising at least one having dental root-periodontal tissue formation promotion effect selected from the group consisting of a compound shown in a following formula (I). (In the formula, R1 and R2 are independently functional groups selected from a group consisting of a substituted or non-substituted group of a linear alkyl group, a branched alkyl group, a linear alkenyl group and a branched alkenyl group with having the carbon number of 3 to 5. R?1 and R?2 are independently a hydrogen atom, hydroxyl group, or alkoxy group having the carbon number of 1 to 3.

Abstract: Agents or pharmaceutical compositions for promoting osteoblast differentiation include purified auraptene or coumarin analogs thereof represented by the following formula 1: wherein R1 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, or a carboxyethyl; R2 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, a carboxyethyl or a coumarinyl; R3 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl or a carboxyethyl; and R4 represents a hydrogen, a C1-C15 liner or branched alkyl, an alkenyl, an alkadienyl or an alkatrienyl.

Abstract: Provided is a composition that, even when used in a very small amount, has the effect of improving bone density and promoting bone growth, and has few side effects, and also provided are a pharmaceutical preparation for promoting bone growth, functional food product, and health food product containing the composition as an active ingredient. The composition can be obtained from any plant part selected from the group consisting of the bud, leaf, bark or wood of a plant belonging to the family Magnoliaceae. The composition comprises at least one selected from the group consisting of fargesin and physiologically acceptable salts, hydrates, and glycosides thereof. The pharmaceutical preparation, functional food product, and health food product comprising this composition as an active ingredient sufficiently improve bone density and promote bone growth, even when used in small amounts, and therefore realize preventive and/or therapeutic effects against bone disease etc. such as osteoporosis.

Abstract: Agents or pharmaceutical compositions for promoting osteoblast differentiation include purified auraptene or coumarin analogs thereof represented by the following formula 1: wherein R1 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, or a carboxyethyl; R2 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, a carboxyethyl or a coumarinyl; R3 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl or a carboxyethyl; and R4 represents a hydrogen, a C1-C15 liner or branched alkyl, an alkenyl, an alkadienyl or an alkatrienyl.

Abstract: A method for screening a substance for treating visceral adiposity syndrome comprises: (1) extracting a total RNA fraction from skeletal muscle collected from non-human mammals of a group to which a predetermined amount of the test substance has been administered and from non-human mammals of a group to which the test substance has not been administered; (2) quantifying the expression quantity of mRNA in the total RNA fraction extracted that encodes a glucose transporter gene by a specific method; and (3) comparing and analyzing the quantity of the test substance ingested, the body weight gain, and the expression quantity of RNA encoding the glucose transporter gene during the administration period for the non-human mammals of the test substance-administered group to these quantities for the non-human mammals that constitute the test substance-unadministered group to thereby determine the effect of the test substance on the metabolic syndrome.

Abstract: The present invention provides the pharmaceutical compositions, the pharmaceutical preparations thereof as an active ingredient, the health food, the food with health-promoting benefits and the like. The present invention provides the above-mentioned pharmaceutical preparations and the like comprising at least one of the compound shown in the following formula (I), physiologically acceptable salt thereof, or hydrate thereof. (wherein, R?1, R?2, and R?3 are independently a hydrogen atom, OH, or alkoxy group having C1 to C3, respectively. R1, R2, and R3 are independently a hydrogen atom or alkenyl group having C3 to C5, respectively).

Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating periodontal disease comprising at least one having dental root-periodontal tissue formation promotion effect selected from the group consisting of a compound shown in a following formula (I). (In the formula, R1 and R2 are independently functional groups selected from a group consisting of a substituted or non-substituted group of a linear alkyl group, a branched alkyl group, a linear alkenyl group and a branched alkenyl group with having the carbon number of 3 to 5. R?1 and R?2 are independently a hydrogen atom, hydroxyl group, or alkoxy group having the carbon number of 1 to 3.

Abstract: This invention relates to drinks and foods having osteogenetic function, each of which comprises as an active ingredient an effective amount of a culture of a propionic acid bacterium and/or a lactic acid bacterium, said culture containing 2-amino-3-carboxy-1,4-naphthoquinone; and preventives and/or remedies for metabolic bone diseases, each of which comprises as an active ingredient a naphthoquinone compound selected from the group consisting of 2-amino-3-carboxy-1,4-naphthoquinone, 1,4-naphthoquinone, 2-hydroxy-1,4-naphthoquinone, 2,3-dichloro-1,4-naphthoquinone, 5-hydroxy-1,4-naphthoquinone, 8-hydroxy-1,4-naphthoquinone, 2-(?-hydroxy-?-methylpentenyl)-5,8-dihydroxy-1,4-naphthoquinone and salts thereof. These cultures and naphthoquinones promote bone metabolism and increase bone mass and bone strength.

Abstract: The present invention provides a highly safe pharmaceutical composition for preventing and/or treating bone disease, a pharmaceutical preparation comprising thereof, a health food comprising thereof, a functional food comprising thereof. Since the present invention comprises the arylheptanoid compound shown in the following formula (I) and the derivatives thereof, it enables to prevent and/or treat the bone disease. (In the formula (I), R1 and R5 are a functional group selected from the group consisting of a hydrogen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R2, R3, and R4 are a functional group selected from the group consisting of a hydrogen atom, an oxygen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R5 may be bound on meta-position against heptylene group of another aryl group to form a ring.

Abstract: The present invention provides the pharmaceutical compositions, the pharmaceutical preparations thereof as an active ingredient, the health food, the food with health-promoting benefits and the like. The present invention provides the above-mentioned pharmaceutical preparations and the like comprising at least one of the compound shown in the following formula (I), physiologically acceptable salt thereof, or hydrate thereof. (wherein, R?1, R?2, and R?3 are independently a hydrogen atom, OH, or alkoxy group having C1 to C3, respectively. R1, R2, and R3 are independently a hydrogen atom or alkenyl group having C3 to C5, respectively).

Abstract: The present invention relates to a protein having an activity of giving a lysozyme insensitivity to a lysozyme-sensitive microorganism belonging to Corynebacterium glutamicum; DNA which codes for the protein; a recombinant vector containing the DNA; a transformant obtained by introducing the recombinant vector into a host cell; a bacterium having a lysozyme sensitivity in which the activity of the protein is inactivated; and a method for producing an amino acid using the bacterium.

Abstract: The present invention has an object to provide a novel therapeutic agent for hypercalcemia and bone diseases, and a novel compound capable of being used as an active ingredient of the therapeutic agent. The present invention is a therapeutic agent for hypercalcemia or bone diseases, comprising as an active ingredient a reveromycin A derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof. (R represents a hydroxyl-protecting group releasable under acidic conditions.

Abstract: This invention relates to drinks and foods having osteogenetic function, each of which comprises as an active ingredient an effective amount of a culture of a propionic acid bacterium and/or a lactic acid bacterium, said culture containing 2-amino-3-carboxy-1,4-naphthoquinone; and preventives and/or remedies for metabolic bone diseases, each of which comprises as an active ingredient a naphthoquinone compound selected from the group consisting of 2-amino-3-carboxy-1,4-naphthoquinone, 1,4-naphthoquinone, 2-hydroxy-1,4-naphthoquinone, 2,3-dichloro-1,4-naphthoquinone, 5-hydroxy-1,4-naphthoquinone, 8-hydroxy-1,4-naphthoquinone, 2-(?-hydroxy-?-methylpentenyl)-5,8-dihydroxy-1,4-naphthoquinone and salts thereof. These cultures and naphthoquinones promote bone metabolism and increase bone mass and bone strength.

Abstract: The present invention relates to a penicillin binding protein, DNA encoding the protein and methods of producing L-glutamic acid in Corynebacterium glutamicum, which has a reduction of penicillin binding protein activity.

Abstract: The present invention relates to a polypeptide having the activity of N-acetylglucosamine-1-phosphate uridyltransferase (hereinafter referred to as GlmU), a DNA coding for the polypeptide, a recombinant DNA containing the DNA, a transformant carrying the recombinant DNA, a method of culturing the transformant for producing the GlmU polypeptide, and a method of culturing the transformant for producing uridine 5?-diphosphate-N-acetylglucosamine. According to the present invention, mass-scale production of the GlmU polypeptide derived from microorganisms belonging to the genus Corynebacterium glutamicum has been enabled by genetic recombinant technology. By using the enzyme, uridine 5?-diphosphate-N-acetylglucosamine can be produced efficiently.

Abstract: The present invention relates to a protein having an activity of giving a lysozyme insensitivity to a lysozyme-sensitive microorganism belonging to Corynebacterium glutamicum; DNA which codes for the protein; a recombinant vector containing the DNA; a transformant obtained by introducing the recombinant vector into a host cell; a bacterium having a lysozyme sensitivity in which the activity of the protein is inactivated; and a method for producing an amino acid using the bacterium.